Method for administering insulin to the buccal region
AssigneeGenerex Pharmaceuticals Incorporated
InventorPankaj Modi
Life of this patent
Estimating the term…
Loading patent…
AssigneeGenerex Pharmaceuticals Incorporated
InventorPankaj Modi
Estimating the term…
A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. Each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation. Methods for administering insulin to the buccal region are also disclosed.
A method for administering insulin to the buccal mucosa comprising spraying an effective amount of said insulin to the buccal mucosa using a metered dose inhaler, while resisting substantial inhalation of said insulin.
Dependencies are inferred from the claim text.